Merck and Schering-Plough said Wednesday they will pay $41.5 million to settle lawsuits claiming the drugmakers, partners on two blockbuster cholesterol drugs, delayed unfavorable study results because they would hurt sales. Data released last year showed Vytorin to be no more effective than an older, less expensive cholesterol treatment, and cast doubt on the effectiveness of Zetia. The suits, brought by consumers, insurers and others who paid for the drugs, questioned both their effectiveness and their safety.
Merck, Schering-Plough to Pay $42 Million in Vytorin Settlement
The Associated Press
August 6, 2009